Table II.
Effects of Different Medications on New‐Onset Diabetes
| Study | No. of Subjects | Ages | Comment |
|---|---|---|---|
| LIFE | 919 | 55–85 | Losartan (ARB): Atenolol (β blocker) (HCTZ added)—25% lower incidence (13 vs. 17.5/1000 patient‐yr) |
| HOPE | 5720 | 55+ | ACE inhibitor (ramipril)—1.8% lower incidence: other medications |
| SCOPE | 4964 | 70–89 (76*) | Candesartan (ARB)‐based therapy; 20% trend to reduction of new‐onset diabetes: other medications |
| ALLHAT | 33,000 | 67* | 3.5% Fewer cases of diabetes with lisinopril than with chlorthalidone |
| INVEST | >16,000 | 1.1% Fewer new‐onset diabetes in CCB/ACE compared with β blocker/diuretic | |
| INSIGHT | 1.3% higher with diuretics compared to CCB | ||
| LIFE=Losartan Intervention for End Point Reduction in Hypertension study; HOPE=Heart Outcomes Prevention Evaluation; SCOPE=Study on Cognition and Prognosis in the Elderly; ALLHAT=Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial; INVEST=International Verapamil SR and Trandolapril Study; INSIGHT=International Nifedipine‐GITS Study: Intervention as a Goal in Hypertension Treatment; ARB=angiotensin receptor blocker; HCTZ=hydrochlorothiazide; ACE=angiotensin‐converting enzyme; CCB=calcium channel blocker; *mean age | |||